| Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients.Ren Fail | PMID 36856148PMC9980412 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial.Emerg Microbes Infect | PMID 36877135PMC10026809 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.Lancet Respir Med | PMID 36958364PMC10027334 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.J Dermatolog Treat | PMID 37036183无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of the efficacy and safety of an oral sulfate solution and 3-L polyethylene glycol on bowel preparation before colonoscopy: a phase III multicenter randomized controlled trial.Gastrointest Endosc | PMID 37422241无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.Am J Ophthalmol | PMID 37544495PMC11040591 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.J Am Acad Dermatol | PMID 37553030无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.J Thorac Oncol | PMID 37574132无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.J Thorac Oncol | PMID 37597750无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial.Rheumatol Int | PMID 37650921无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.Semin Arthritis Rheum | PMID 37660536无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.Diabetes Obes Metab | PMID 37661308无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.Breast Cancer Res Treat | PMID 37676450PMC10564670 | 2023-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.Br J Haematol | PMID 37691005无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).Ann Rheum Dis | PMID 37696589PMC10646837 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.Clin Pharmacol Ther | PMID 37696652无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).Ann Rheum Dis | PMID 37699654PMC10646845 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.Diabetes Obes Metab | PMID 37724698无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.Diabetes Obes Metab | PMID 37732487无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.Adv Ther | PMID 37770770PMC10611639 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV.Adv Ther | PMID 37776478PMC10611592 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial.World J Urol | PMID 37792009无 PMCID | 2023-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.Ann Oncol | PMID 37797734无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.Eur Urol | PMID 37833178无 PMCID | 2023-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis.Clin Ther | PMID 37872059无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-impact laparoscopy in colorectal resection-A multicentric randomised trial comparing low-pressure pneumoperitoneum plus microsurgery versus low-pressure pneumoperitoneum alone: The PAROS II trial.Colorectal Dis | PMID 37897108无 PMCID | 2023-Dec | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.Nat Med | PMID 37919438PMC10719084 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.ESMO Open | PMID 37922691PMC10774966 | 2023-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.Lancet Haematol | PMID 37922925无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.Lancet Oncol | PMID 37926100无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.Acta Oncol | PMID 37934081无 PMCID | 2023-Dec | 0.45 | The record describes a randomized Phase III trial in oncology (small cell lung cancer) and meets the trial design criteria, but the provided metadata (title only, no abstract) does not contain explicit signals for the required efficacy outcomes (e.g., survival, progression, recurrence). Therefore, eligibility cannot be definitively established. | 待处理 |
| Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 37944541无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.Lancet Oncol | PMID 37949086无 PMCID | 2023-Dec | 0.90 | The trial is a randomized, phase 2/3 study of an HPV vaccine with drug intervention and original results, but its primary endpoint is immunogenicity (geometric mean titre ratio) and safety, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the criterion for a time-to-event primary/key secondary endpoint. | 待处理 |
| Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.Eur J Cancer | PMID 37976633无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 37979588PMC10682370 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.ESMO Open | PMID 37988950PMC10774956 | 2023-Dec | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.Atherosclerosis | PMID 38016401无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.Lancet Haematol | PMID 38030318无 PMCID | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 38039991无 PMCID | 2023-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 38039993无 PMCID | 2023-Dec | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.Br J Psychiatry | PMID 38108319PMC10727911 | 2023-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clin Infect Dis | PMID 37466374PMC10686947 | 2023-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Clin Infect Dis | PMID 37539715PMC10686959 | 2023-Nov-30 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J Med | PMID 37870976无 PMCID | 2023-Nov-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.Arch Osteoporos | PMID 38030806PMC10687120 | 2023-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case.Radiat Oncol | PMID 38031125PMC10685528 | 2023-Nov-29 | 0.85 | The record is a quality assurance/planning benchmark case report for a phase III randomized breast cancer trial, but it does not report survival, progression, recurrence, death, or other time-to-event efficacy outcomes. It focuses solely on radiotherapy planning compliance and dose metrics. | 待处理 |
| Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.JAMA | PMID 38015220PMC10685882 | 2023-Nov-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.Medicine (Baltimore) | PMID 38013289PMC10681377 | 2023-Nov-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J Med | PMID 37870920无 PMCID | 2023-Nov-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med | PMID 37937763无 PMCID | 2023-Nov-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |